Dapagliflozin improves symptoms and physical limitations in people with heart failure across the spectrum of ejection fractions, according to a pooled analysis of the DEFINE-HF and PRESERVED-HF trials.
“The effects were large, clinically meaningful, and statistically significant,” said Mikhail Kosiborod, MD (Saint Luke’s Mid America Heart Institute, Kansas City, MO), who presented the results Sunday at the European Society of Cardiology 2022 Heart Failure congress. “Collectively, these results provide support for the use of dapagliflozin in patients with heart failure, regardless of ejection fraction.”
Speaking with TCTMD, Kosiborod stressed that trials in heart failure patients with reduced ejection fraction (HFrEF) have shown that dapagliflozin (Farxiga; AstraZeneca), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduces the risk of cardiovascular deaths and hospitalizations while improving health status and quality of life. For patients with HF and preserved ejection fraction (HFpEF), however, “the picture has been a little bit less consistent,” he acknowledged.
Read the full TCTMD article: Dapagliflozin Boosts Health Status Across LVEF Range